Important Safety Information for Lantus®
Prescription Lantus® is for adults with type 2 diabetes or adults and children (6 years and older) with type 1 diabetes who require long-acting insulin for the control of high blood sugar.
Lantus® SoloSTAR® is a disposable insulin delivery device (insulin pen). Needles and the SoloSTAR® pen must not be shared.
DO NOT DILUTE OR MIX LANTUS® WITH ANY OTHER INSULIN OR SOLUTION. It will not work as intended, and you may lose blood sugar control, which could be serious. Do not change your insulin without talking with your doctor. The syringe must not contain any other medication or residue. You should not use Lantus® if you are allergic to insulin. Lantus® is a long-acting insulin you inject just once a day, at the same time each day. You must test your blood sugar levels while using an insulin such as Lantus®.
The most common side effect of insulin, including Lantus®, is hypoglycemia, which may be serious. Other possible side effects may include injection site reactions, including changes in fat tissue at the injection site, and allergic reactions, including itching and rash. In rare cases, some allergic reactions may be life threatening. Tell your doctor about other medicines and supplements you are taking because they can change the way insulin works.
Click here for additional important information for Lantus®.
Important Safety Information for Apidra® (insulin glulisine [rDNA origin] injection)
Apidra® (insulin glulisine [rDNA origin] injection) is for adults with type 1 or type 2 diabetes for the control of high blood sugar.
Apidra® (insulin glulisine [rDNA origin] injection) should normally be used with a longer-acting insulin. Do not use Apidra® (insulin glulisine [rDNA origin] injection) during
a low blood sugar reaction (hypoglycemia) or if you are allergic to insulin glulisine.
Apidra® (insulin glulisine [rDNA origin] injection) differs from regular human insulin by its rapid onset and shorter duration
of action. When used as a mealtime insulin, Apidra® (insulin glulisine [rDNA origin] injection) should be given within 15
minutes before or within 20 minutes after starting a meal. Due to the short duration
of action of Apidra® (insulin glulisine [rDNA origin] injection), patients also require a longer-acting insulin or insulin infusion
pump therapy. Any change of insulin should be made cautiously and only under
medical supervision. Tell your doctor about all other medicines and supplements you are
taking. Glucose monitoring is recommended for all patients with diabetes.
Possible side effects may include low blood sugar; injection site reactions, such as changes
in fat tissue at the injection site; and allergic reactions, such as itching and rash. Less
common, but potentially more serious or life-threatening, is generalized allergy to insulin,
including anaphylactic reactions.
Click here for additional important information for Apidra® (insulin glulisine [rDNA origin] injection)
| The health information contained herein is provided for general educational purposes only.
Your healthcare professional is the single best source of information regarding your health.
Please consult your healthcare professional if you have any questions about your health or
treatment. |
*Based on TRx data from IMS Health, National Prescription AuditTM (Next Generation Prescription Methodology). Time period from May 2003 to July 2007.
Ultra-Fine is a trademark of Becton, Dickinson and Company.
†Needle not included with pen.
